158 related articles for article (PubMed ID: 34967391)
1. Prolonged viral positivity induced recurrent coronavirus disease 2019 (COVID-19) pneumonia in patients receiving anti-CD20 monoclonal antibody treatment: Case reports.
Deveci B; Saba R
Medicine (Baltimore); 2021 Dec; 100(52):e28470. PubMed ID: 34967391
[TBL] [Abstract][Full Text] [Related]
2. Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia.
Lancman G; Mascarenhas J; Bar-Natan M
J Hematol Oncol; 2020 Oct; 13(1):131. PubMed ID: 33008453
[TBL] [Abstract][Full Text] [Related]
3. Prolonged SARS-CoV-2 Infection in Patients Receiving Anti-CD20 Monoclonal Antibodies: A Diagnostic Challenged by Negative Nasopharyngeal RT-PCR and Successful Treatment with COVID-19 High-Titer Convalescent Plasma.
Da Silva L; Klopfenstein T; Gendrin V; Clouet J; Toko L; Richier Q; Leriche T; Nicolas R; Queijo A; Sreiri N; Lacombe K; Zayet S
Viruses; 2023 Nov; 15(11):. PubMed ID: 38005897
[TBL] [Abstract][Full Text] [Related]
4. Remdesivir in Coronavirus Disease 2019 patients treated with anti-CD20 monoclonal antibodies: a case series.
Rüfenacht S; Gantenbein P; Boggian K; Flury D; Kern L; Dollenmaier G; Kohler P; Albrich WC
Infection; 2022 Jun; 50(3):783-790. PubMed ID: 35426564
[TBL] [Abstract][Full Text] [Related]
5. Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products.
Kenig A; Ishay Y; Kharouf F; Rubin L
Clin Immunol; 2021 Jun; 227():108723. PubMed ID: 33838340
[TBL] [Abstract][Full Text] [Related]
6. A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma.
Moore JL; Ganapathiraju PV; Kurtz CP; Wainscoat B
Am J Case Rep; 2020 Oct; 21():e927812. PubMed ID: 33009361
[TBL] [Abstract][Full Text] [Related]
7. Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway.
D'Abramo A; Vita S; Maffongelli G; Beccacece A; Agrati C; Cimini E; Colavita F; Giancola ML; Cavasio A; Nicastri E;
Front Immunol; 2022; 13():911339. PubMed ID: 35711444
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis.
Curtò D; Tomatis F; Gastoldi S; Galbusera M; Noris M; Raimondi F; Lorini FL; Falanga A; Marchetti M; Remuzzi G; Ruggenenti P
Front Immunol; 2021; 12():711915. PubMed ID: 34276706
[TBL] [Abstract][Full Text] [Related]
9. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.
Taha Y; Wardle H; Evans AB; Hunter ER; Marr H; Osborne W; Bashton M; Smith D; Burton-Fanning S; Schmid ML; Duncan CJA
Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):85. PubMed ID: 34969393
[TBL] [Abstract][Full Text] [Related]
10. Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma.
Karataş A; İnkaya AÇ; Demiroğlu H; Aksu S; Haziyev T; Çınar OE; Alp A; Uzun Ö; Sayınalp N; Göker H
Transfus Apher Sci; 2020 Oct; 59(5):102871. PubMed ID: 32694044
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity.
Steiner S; Schwarz T; Corman VM; Gebert L; Kleinschmidt MC; Wald A; Gläser S; Kruse JM; Zickler D; Peric A; Meisel C; Meyer T; Staudacher OL; Wittke K; Kedor C; Bauer S; Besher NA; Kalus U; Pruß A; Drosten C; Volk HD; Scheibenbogen C; Hanitsch LG
Front Immunol; 2022; 13():840126. PubMed ID: 35359967
[TBL] [Abstract][Full Text] [Related]
12. Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia.
Guisado-Vasco P; Carralón-González MM; Aguareles-Gorines J; Martí-Ballesteros EM; Sánchez-Manzano MD; Carnevali-Ruiz D; García-Coca M; Barrena-Puertas R; de Viedma RG; Luque-Pinilla JM; Sotres-Fernandez G; Fernández-Sousa JM; Luepke-Estefan XE; López-Martín JA; Jimeno JM
J Hematol Oncol; 2022 Jan; 15(1):4. PubMed ID: 35012608
[TBL] [Abstract][Full Text] [Related]
13. Favorable Outcome Following Sotrovimab Monoclonal Antibody in a Patient with Prolonged SARS-CoV-2 Omicron Infection with HIV/AIDS.
Adachi E; Saito M; Koga M; Tsutsumi T; Yotsuyanagi H
Intern Med; 2022 Nov; 61(22):3459-3462. PubMed ID: 36070950
[TBL] [Abstract][Full Text] [Related]
14. A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China.
Huang S; Shen C; Xia C; Huang X; Fu Y; Tian L
Med Sci Monit; 2020 Dec; 26():e928755. PubMed ID: 33264276
[TBL] [Abstract][Full Text] [Related]
15. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19.
Hueso T; Pouderoux C; Péré H; Beaumont AL; Raillon LA; Ader F; Chatenoud L; Eshagh D; Szwebel TA; Martinot M; Camou F; Crickx E; Michel M; Mahevas M; Boutboul D; Azoulay E; Joseph A; Hermine O; Rouzaud C; Faguer S; Petua P; Pommeret F; Clerc S; Planquette B; Merabet F; London J; Zeller V; Ghez D; Veyer D; Ouedrani A; Gallian P; Pacanowski J; Mékinian A; Garnier M; Pirenne F; Tiberghien P; Lacombe K
Blood; 2020 Nov; 136(20):2290-2295. PubMed ID: 32959052
[TBL] [Abstract][Full Text] [Related]
16. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience.
Weinbergerová B; Demel I; Víšek B; Válka J; Čerňan M; Jindra P; Novák J; Stejskal L; Kovácsová F; Kabut T; Szotkowski T; Hájek R; Žák P; Cetkovský P; Král Z; Mayer J
Hematol Oncol; 2022 Apr; 40(2):280-286. PubMed ID: 35120267
[TBL] [Abstract][Full Text] [Related]
17. Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies.
Magyari F; Pinczés LI; Páyer E; Farkas K; Ujfalusi S; Diószegi Á; Sik M; Simon Z; Nagy G; Hevessy Z; Nagy B; Illés Á
Ann Hematol; 2022 Oct; 101(10):2337-2345. PubMed ID: 35836007
[TBL] [Abstract][Full Text] [Related]
18. Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates.
Ioannou P; Katsigiannis A; Papakitsou I; Kopidakis I; Makraki E; Milonas D; Filippatos TD; Sourvinos G; Papadogiannaki M; Lydaki E; Chamilos G; Kofteridis DP
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992465
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.
Kremer AE; Kremer AN; Willam C; Völkl S; Verhagen J; Achenbach S; van der Meijden ED; Lang V; Aigner M; Maier C; Tenbusch M; Korn K; Lutzny-Geier G; Spoerl S; Strauß R; Vetter M; Überla K; Neurath MF; Mackensen A; Schiffer M; Hackstein H
Eur J Immunol; 2021 Oct; 51(10):2478-2484. PubMed ID: 34350584
[TBL] [Abstract][Full Text] [Related]
20. Resolution of One-Year Persisting COVID-19 Pneumonia and Development of Immune Thrombocytopenia in a Follicular Lymphoma Patient With Preceding Rituximab Maintenance Therapy: A follow-up Report and Literature Review of Cases With Prolonged Infections.
Yasuda H; Mori Y; Chiba A; Bai J; Murayama G; Matsushita Y; Miyake S; Komatsu N
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):e810-e816. PubMed ID: 34393077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
